Biotech Essentials

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 31.08.2021.

Pharmacology
Form 10-K
Alford plea
Fibroblast growth factor
Smallpox
B cell

Healthcare

@JNJInnovation shared
On Aug 25, 2021
RT @JNJNews: JUST IN: Interim Phase 1/2a data suggest booster dose of our #COVID19 vaccine generates rapid, robust increase in spike-binding antibodies in adults (n=17). https://t.co/Sh2r3JybOX The Janssen COVID-19 Vaccine has not been approved/licensed by FDA. https://t.co/Xnh5QXScdQ https://t.co/kyaWNVTWkL
Open
Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

Johnson & Johnson COVID-19 vaccine booster, after single dose primary regimen, provided rapid and robust increase in spike-binding antibodiesNew studies build on data demonstrating strong ...

@matthewherper shared
On Aug 27, 2021
RT @megtirrell: The power of mRNA technology is obvious now. But in early 2020, it was a huge bet to take on a quickly spreading novel pathogen. Released today, a documentary from CNBC Digital on how two teams, at Moderna & Pfizer/BioNTech, did it. Produced by @samrega: https://t.co/BLWsKe2SGZ
Open
A race against Covid: How Moderna and Pfizer-BioNTech developed vaccines in record time

A race against Covid: How Moderna and Pfizer-BioNTech developed vaccines in record time

The teams at Moderna, Pfizer and BioNTech recount the historic race to develop Covid-19 vaccines in a newly released documentary by CNBC.

@matthewherper shared
On Aug 30, 2021
Big money: Flagship’s uber-platform play Laronde rakes in $440M to chase programmable ‘eRNA’ https://t.co/oxjoTs9HJ3
Open
Big money: Flagship's uber-platform play Laronde rakes in $440M to chase programmable 'eRNA'

Big money: Flagship's uber-platform play Laronde rakes in $440M to chase programmable 'eRNA'

With the success of Moderna, parent company Flagship Pioneering has become the mothership for even more audacious next-gen platform plays. Investors like what they see, and now they've ...

@sciam shared
On Aug 28, 2021
Some cancer centers pioneer new therapies more often than others. That takes smart strategies to find promising candidates, test them in innovative trials, and forge partnerships with industry.  [Sponsored by @HMHNewJersey] https://t.co/yA6w6FG5rl
Open
Novel Cancer Therapies Begin With Innovative Trials

Novel Cancer Therapies Begin With Innovative Trials

Cancer research centers play a vital role in conducting clinical trials of promising therapies. But not all drug development partnerships are created equal.

@SWLifeSciences shared
On Aug 25, 2021
With Nov PDUFA Date, FDA Could Approve Legend Biotech's Lead Cell Therapy Soon: https://t.co/2rP6NBiRUx BTIG noted cilta-cel has potential "to take significant market share within the relapsed-refractory multiple myeloma market & establish a best-in-class profile." $LEGN https://t.co/01SPTrOYHv
Open
With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon

A BTIG report noted that Legend Biotech's cilta-cel has the potential to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class ...

@emilylmullin shared
On Aug 25, 2021
RT @antonioregalado: We asked the question, what is a Ginkgo worth? One of the largest biotech IPOs (via a SPAC) ever for Ginkgo Bioworks, a synbio company with fantastic messaging but not much revenue. https://t.co/Uhr4PHkwed
Open
Is Ginkgo’s synthetic-biology story worth $15 billion?

Is Ginkgo’s synthetic-biology story worth $15 billion?

Jason Kelly has promised a manufacturing revolution with DNA. Just don’t ask him to make any products.

@emilylmullin shared
On Aug 25, 2021
For @leaps_org, I talked to @DoctorNatasha about how Delta is affecting children, how parents can keep their kids safe, and what we can expect as schools open again. Listen to the podcast here: https://t.co/kdNjHXomCh
Open
New Podcast: Dr. Natasha Burgert Discusses Kids and the Delta Variant

New Podcast: Dr. Natasha Burgert Discusses Kids and the Delta Variant

"Making Sense of Science" is a monthly podcast that features interviews with leading medical and scientific experts about the latest developments and the big ethical and societal questions ...

@BIODeutschland shared
On Aug 25, 2021
Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/ZOFgSKC6yE
Open
Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large …

Read more: Healthcare
weekly 31.08.2021
View archives
Back to home

Subscribe to Biotech Essentials - Biotech & Healthcare.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech Essentials - Biotech & Healthcare.
Privacy Policy

Sign up for the weekly Biotech Essentials - Biotech & Healthcare newsletter

Never again miss anything or anyone that matter in Biotech Essentials

Sign up and receive the Biotech Essentials - Biotech & Healthcare weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy